loading

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

Acadia wins patent appeal for key drug composition - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Acadia gets court approval related to Nuplazid patent - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review

Jun 10, 2025
pulisher
Jun 10, 2025

ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACA - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine

Jun 10, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360

Jun 09, 2025
pulisher
Jun 09, 2025

Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Drug - U.S. News & World Report

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo

Jun 09, 2025
pulisher
Jun 06, 2025

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $30 Following Patent Win | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell: Laura Brege Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Secu - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Securities | ACAD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 | ACAD Stock News - GuruFocus

Jun 05, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):